Raymond James & Associates Has $2.06 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Raymond James & Associates decreased its position in shares of Haemonetics Co. (NYSE:HAE) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,050 shares of the medical instruments supplier’s stock after selling 8,751 shares during the period. Raymond James & Associates’ holdings in Haemonetics were worth $2,057,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of HAE. American Century Companies Inc. increased its holdings in shares of Haemonetics by 163.5% during the first quarter. American Century Companies Inc. now owns 17,407 shares of the medical instruments supplier’s stock worth $1,100,000 after buying an additional 10,802 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Haemonetics by 3.1% during the first quarter. PNC Financial Services Group Inc. now owns 12,802 shares of the medical instruments supplier’s stock worth $809,000 after buying an additional 387 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Haemonetics by 300.3% during the first quarter. Bank of Montreal Can now owns 33,039 shares of the medical instruments supplier’s stock worth $2,033,000 after buying an additional 24,785 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Haemonetics by 1.9% during the first quarter. Rhumbline Advisers now owns 148,770 shares of the medical instruments supplier’s stock worth $9,405,000 after buying an additional 2,817 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Haemonetics by 10.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,732 shares of the medical instruments supplier’s stock worth $1,184,000 after buying an additional 1,788 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Barrington Research reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $84.21 on Wednesday. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The firm has a market cap of $4.28 billion, a P/E ratio of 34.23, a P/E/G ratio of 2.01 and a beta of 0.36. The firm has a 50 day simple moving average of $78.56 and a 200 day simple moving average of $82.76. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $95.26.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. Haemonetics’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.85 earnings per share. Sell-side analysts predict that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.